Whalesbook
📉 The Financial Deep Dive
The Numbers: Gland Pharma Limited announced a strong third quarter for FY26, with consolidated revenue from operations growing an impressive 22% year-on-year (YoY) to ₹16,954 Mn from ₹13,841 Mn in Q3 FY25. For the nine-month period ended December 31, 2025, revenue saw a 12% YoY increase, reaching ₹46,879 Mn. Adjusted EBITDA demonstrated robust growth, up 25% YoY to ₹4,490 Mn in Q3 FY26, with the margin holding steady at 26%. Over nine months, adjusted EBITDA grew 26% YoY to ₹11,582 Mn with a 25% margin. Profitability saw a significant uplift, with adjusted Profit After Tax (PAT) surging 37% YoY to ₹2,797 Mn in Q3 FY26. The adjusted PAT margin improved by 170 basis points (bps) to 16%. For the nine-month period, adjusted PAT rose 33% YoY to ₹6,789 Mn, with margins expanding 230 bps to 14%.
An exceptional item of ₹243.46 Mn was recognized due to provisions related to new labor codes. Standalone revenue increased 16% YoY to ₹11,790 Mn in Q3 FY26, though the standalone adjusted EBITDA margin saw a slight dip to 37% from 39% in the prior year quarter, while the standalone adjusted PAT margin remained stable at 28%.
The Quality: The consolidated performance highlights healthy revenue acceleration coupled with margin stability and improvement in PAT. The substantial 37% YoY PAT growth, aided by margin expansion, indicates improved operational leverage or better product mix. The operating cash flow for the nine months stood at ₹6,269 Mn, supporting capital expenditure of ₹3,566 Mn during the same period.
The Grill: Management expressed confidence in maintaining growth momentum, citing new product launches, ramp-ups in CDMO contracts, and operational efficiencies. R&D investment increased to 5.4% of revenue, reflecting a focus on complex product development and filings. The company's strategic focus on expanding its product pipeline is evident with 9 ANDA filings and 4 approvals in the US during the quarter. The launch of its first partnered GLP-1 drug (Liraglutide) in the US and securing a new CMO contract for a complex Nano Drug Delivery System in Oncology are significant steps towards long-term revenue visibility. Cenexi's performance improved to breakeven with strong revenue traction, adding another positive note.
🚩 Risks & Outlook
Specific Risks: While the outlook is positive, potential risks include execution delays in capacity expansions (e.g., the new ampoule line by 2027), intense competition in key markets like the US, and evolving regulatory landscapes. The slight decrease in standalone EBITDA margin warrants monitoring.
The Forward View: Investors should watch the successful integration of new contracts, continued product pipeline execution, and performance in key geographies. The company's strategy appears geared towards sustainable growth driven by complex product development and increasing CDMO contributions.